Open Access

Downregulation of MCM8 expression restrains the malignant progression of cholangiocarcinoma

  • Authors:
    • Jingcheng Hao
    • Haimin Deng
    • Yuan Yang
    • Lidan Chen
    • Qiang Wu
    • Pei Yao
    • Junen Li
    • Bowen Li
    • Xueli Jin
    • Haiqing Wang
    • Huaxin Duan
  • View Affiliations

  • Published online on: September 15, 2021     https://doi.org/10.3892/or.2021.8186
  • Article Number: 235
  • Copyright: © Hao et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Cholangiocarcinoma (CCA) is a highly aggressive malignant tumor with an extremely poor prognosis. Minichromosome maintenance 8 homologous recombination repair factor (MCM8) is a helicase involved in the elongation step of DNA replication and tumorigenesis. In the present study, the clinical significance and biological function of MCM8 in CCA were investigated. The expression levels of MCM8 in CCA and paracancerous tissues were analyzed using immunohistochemical staining. The potential mechanisms underlying MCM8 and the biological effects of MCM8 in CCA cells were explored using in vitro assays and in vivo mouse xenograft models. The high expression levels of MCM8 in CCA has important clinical significance in predicting disease progression. Knockdown of MCM8 decreased proliferation, promoted apoptosis and suppressed migration of CCA cells. MCM8 knockdown also suppressed tumor growth in vivo. Mechanistically, MCM8 knockdown led to the abnormal downregulation of survivin, XIAP, HSP27, IGF‑1sR, sTNF‑R1, sTNF‑R2, TNF‑α and TNF‑β. Furthermore, downregulation of MCM8 expression inhibited the PI3K/Akt signaling pathway and induced the MAPK9 signaling pathway. MCM8 promoted the malignant progression of CCA, indicating that inhibition of MCM8 may have the potential to serve as a novel molecular targeted therapy.
View Figures
View References

Related Articles

Journal Cover

November-2021
Volume 46 Issue 5

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Hao J, Deng H, Yang Y, Chen L, Wu Q, Yao P, Li J, Li B, Jin X, Wang H, Wang H, et al: Downregulation of MCM8 expression restrains the malignant progression of cholangiocarcinoma. Oncol Rep 46: 235, 2021
APA
Hao, J., Deng, H., Yang, Y., Chen, L., Wu, Q., Yao, P. ... Duan, H. (2021). Downregulation of MCM8 expression restrains the malignant progression of cholangiocarcinoma. Oncology Reports, 46, 235. https://doi.org/10.3892/or.2021.8186
MLA
Hao, J., Deng, H., Yang, Y., Chen, L., Wu, Q., Yao, P., Li, J., Li, B., Jin, X., Wang, H., Duan, H."Downregulation of MCM8 expression restrains the malignant progression of cholangiocarcinoma". Oncology Reports 46.5 (2021): 235.
Chicago
Hao, J., Deng, H., Yang, Y., Chen, L., Wu, Q., Yao, P., Li, J., Li, B., Jin, X., Wang, H., Duan, H."Downregulation of MCM8 expression restrains the malignant progression of cholangiocarcinoma". Oncology Reports 46, no. 5 (2021): 235. https://doi.org/10.3892/or.2021.8186